A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer
A phase 3 trial of XZP-3287 in advanced solid tumours, run by Xuanzhu Biopharmaceutical Co., Ltd., active and no longer recruiting.
Overview
A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer is a phase 3 interventional study registered as NCT05257395 by Xuanzhu Biopharmaceutical Co., Ltd., with 397 participants enrolled, started 2022-03-14 and due to reach its primary completion in 2025-12-05. Interventions recorded: XZP-3287+ Letrozole/Anastrozole and Placebo + Letrozole/Anastrozole.
Similar pages
not linked directly; found by shared links- TrialA Phase I/II Study of XZP-3287 in Metastasis Solid Tumors
Shares XZP-3287, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors
Shares Xuanzhu Biopharmaceutical and the tag pipeline.
- TrialA Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer
Shares XZP-3287, Xuanzhu Biopharmaceutical.
- TrialInvestigation of a Therapeutic Vaccine (ACIT-1) in Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPlasmodium Immunotherapy for Advanced Malignant Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialFirst-in-Human Study of ICT01 in Patients With Advanced Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.